On November 6, AstraZeneca (AZ) released its Q3 2025 results. Total revenue for the first 9 months was USD 43.2 billion (+11%), of which product revenue accounted for USD 43.1 billion (+11%). R&D investment reached USD 10.4 billion, a year-on-year increase of 16%. Broken down by region, between Q1 and Q3, revenue from the US market was USD 18.5 billion (+11%) while emerging markets contributed USD 11.7 billion (+13%), with China revenue at USD 5.3 billion (+5%), accounting for 12% of AZ's global market share.

The company divides its business into five segments: oncology, CVRM (cardiovascular, renal and metabolic diseases), respiratory and immunology (R&I), vaccines and immune therapies (V&I), and rare diseases. These segments contributed revenues of USD 18.6 billion (+16%), USD 9.9 billion (+5%), USD 6.5 billion (+13%), USD 826 million (+2%) and USD 6.8 billion (+6%) respectively. Oncology drugs remain AZ's largest business segment, accounting for 43% of total product revenue.

According to PharmCube's NextBiopharm® database, AZ's top-selling Farxiga (dapagliflozin) has enjoyed double-digit growth since its 2015 launch. Click here to request a free trial for NextBiopharm®.